Physician profile
Allyson Roberts
NPI 1750993341
$3,187.25
in general payments reported to CMS, 2019-2025
31 companies · $341 in 2025
The $341 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,175 · 2022: $585 · 2023: $649 · 2024: $437 · 2025: $341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,427.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,427.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $800.00 | 2021 | |
| Abbvie INC. | $716.57 | 2021-2025 | |
| Novo Nordisk INC | $230.86 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $204.07 | 2021-2024 | Mounjaro, Trulicity, Zepbound |
| Merck Sharp & Dohme LLC | $150.20 | 2021-2025 | Gardasil 9, Vaxelis, M-M-R II |
| Astrazeneca Pharmaceuticals LP | $113.47 | 2021-2024 | Breztri, Airsupra |
| Glaxosmithkline, LLC. | $107.47 | 2021-2023 | Shingrix, Arexvy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $92.15 | 2025 | Caplyta |
| Amarin Pharma, INC. | $74.20 | 2021 | |
| Boston Scientific Corporation | $65.88 | 2022-2025 | Wavewriter Alpha Prime 16 |
| Pfizer INC. | $59.21 | 2021-2025 | |
| Corium, LLC | $57.46 | 2024 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $54.76 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $48.51 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $44.56 | 2024-2025 | Voquezna |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $40.72 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $29.39 | 2024-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $29.26 | 2022-2023 | Qelbree |
| Avion Pharmaceuticals | $27.90 | 2022 | |
| Organon LLC | $26.53 | 2023-2025 | Nexplanon |
| Astellas Pharma US INC | $25.44 | 2025 | Veozah |
| Janssen Pharmaceuticals, INC | $22.15 | 2023 | Spravato |
| Corcept Therapeutics | $22.12 | 2024 | Korlym |
| Ultragenyx Pharmaceutical INC. | $21.49 | 2022 | |
| Tris Pharma INC | $20.06 | 2024 | Dyanavel Xr |
| Inspire Medical Systems, INC. | $18.93 | 2024 | Inspire |
| Upsher-Smith Laboratories LLC | $18.89 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.84 | 2024 | |
| Idorsia Pharmaceuticals US INC | $17.81 | 2023 | Quviviq |
| Exact Sciences Corporation | $16.14 | 2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $13.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allyson Roberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.